LC-SF-14

• Description:

  LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR (IC50 values are 71.6 and 8.9 nM, respectively) . LC-SF-14 inhibits FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation. LC-SF-14 inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM) . LC-SF-14 has antitumor activity in the SNU-16 xenograft mouse model. LC-SF-14 can be used in FGFR2-driven gastric cancer research[1].

• UNSPSC:

  12352211

• Target:

  ERK; FGFR; p38 MAPK; SHP2

• Related Pathways:

  MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Field of Research:

  Cancer

• Smiles:

  O=C(NC1=CC=CC(SC2=NC=C(N3CCC(C)(N)CC3)N=C2N)=C1Cl)CCC(N4CCN(C5=CC=C(NC6=NC=NC(N(C)C(NC7=C(Cl)C(OC)=CC(OC)=C7Cl)=O)=C6)C=C5)CC4)=O

• Molecular Formula:

  C44H50Cl3N13O5S

• Molecular Weight:

  979.38

• References & Citations:

  [1]Zheng L, et al. Discovery of LC-SF-14, a selective dual inhibitor of SHP2 and FGFR for the treatment of FGFR2-driven gastric cancer. Eur J Med Chem. 2025 May 11;294:117745.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported